emergingopp_icon
Description

How is the biotech sector likely to be impacted by Brexit, both in the UK and the EU? This panel discussion will address some key issues and questions that Brexit may raise, with a particular focus on cells and gene therapy development and commercialization. The panelists will consider all stages of these products' life cycle, to explore how each step may be affected by Brexit, from R&D through clinical trials, marketing authorization application and market supply as well as manufacturing and pharmacovigilance issues. Both perspectives of continental Europe and the UK will be discussed, taking into account the scenarios remaining on the table when the panel discussion will take place

Ability Level: All

Session ID: 503500

Tags